Human prolactin (hPRL) derived from either amniotic fluid (AF) or pituitary was tested for its passage capability through amniotic and chorionic membranes placed in an in vitro perfusion chamber. The passage of both ‘cold’ and labelled prolactin were investigated using intact monomeric iodinated hPRL isolated from amniotic fluid which also served as a tracer in a homologous double antibody radioimmunoassay used for prolactin determinations. Throughout 4 h incubation period at 37 °C, there was no passage of ‘cold’ hPRL from either of the sources across either direction. Also, in contrast to free iodine ions, there was no passage of intact labelled prolactin in either direction. Decomposition of labelled prolactin occurred only in the chorionic side, and only decomposed labelled prolactin molecules passed into the amniotic side. These became detectable 1 h after commencement of incubation. These results may explain the long half-life and the high concentration of hPRL in amniotic fluid, and also suggest that the source of AF hPRL is not maternal.

Keywords:
Prolactin, Chorion, Amnion
This content is only available via PDF.
© 1979 S. Karger AG, Basel
1979
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.